EDP Biotech

About EDP Biotech

EDP Biotech, now part of New Day Diagnostics, develops and commercializes early-stage disease detection tests. The company was founded in 2005 by Herbert F. Steed and is headquartered in Knoxville, Tennessee. Its flagship product is ColoPlex, a blood-based biomarker test designed for the early detection of colorectal cancer, which has received FDA Breakthrough Device Designation. The test aims to provide a more accessible and less invasive alternative to traditional screening methods like colonoscopies, thereby increasing screening compliance rates.

The company's business model focuses on developing and commercializing these diagnostic tests, targeting healthcare providers and laboratories. Revenue is generated from the sale of the test kits. In October 2023, EDP Biotech was acquired by New Day Diagnostics, a transaction aimed at accelerating the commercialization of ColoPlex and expanding the portfolio of diagnostic solutions. This strategic acquisition combines EDP's diagnostic technology with New Day's commercialization expertise and resources.

Eric Mayer, who joined as CEO of EDP Biotech in 2014, now serves as the CEO of the combined entity, New Day Diagnostics. His leadership is focused on bringing accessible and accurate diagnostic tools to the market to improve patient outcomes through early disease detection.